Acumen pharmaceuticals, inc.ABOS.US Overview

US StockHealthcare

(No presentation for ABOS)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

ABOS Overall Performance

ABOS AI Analysis & Strategy

ABOS Recent Performance

-1.28%

Acumen pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

ABOS PowerScanner

ABOS Key Information

ABOS Valuation Metrics

ABOS Earnings Table

ABOS Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.